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LIST OF DEFINITIONS 
Definitions  
The following terms are defined according to their relevant sources, in order to describe 
the focus of this study: 
Adverse drug reactions: 
Adverse drug reactions (ADRs) are defined as an injury caused by taking medication. It 
may occur following a single dose or a prolonged use of a drug or a combination of two 
or more drugs. 
Attitudes: 
Attitude is a settled way of thinking or feeling about something (Brown & Bussell, 
2011)In this study, attitude refers to how people think ADRs occur and how they feel 
about them (Brown & Bussell, 2011). 
Awareness: 
Awareness is described as knowledge or perception of a situation or fact or a concern 
about and well-informed interest in a particular situation or development In this study, 
awareness is used as a description of knowledge about ADRs and the DDIs leading to 
these reactions when ARVs and other medication are taken (Bogolubova et al., 2018). 
Drug–drug interactions: 
Drug–drug interactions occur when a drug affects the activity of another drug when both 
are taken together (Gilligan et al., 2011). 
Experience: 
Experience is defined as practical contact with an observation of facts or events. It 






Adverse drug reactions (ADRs) are undesirable side effects that occur even when a drug is 
administered at the proper dose and correctly for an appropriate indication. Given the high 
prevalence of Human Immuno-deficiency Virus (HIV) in South Africa, more than 3 million people 
are reported to be taking antiretrovirals (ARVs). Therefore, patients taking ARVs may also be 
taking other medicines due to other existing diseases such as diabetes, hypertension, and 
tuberculosis. The concurrent use of other medicines with ARVs may increase the potential of 
ADRs, snowballing to increased numbers of hospitalisations and contributing to mortality rates. 
The study investigated awareness, attitudes, and experiences of ADRs among patients taking 
ARVs. This was a descriptive cross-sectional study using a questionnaire that contained close-
ended questions to which patients responded. The study was conducted at a selected public hospital 
in KwaZulu-Natal. Questionnaires were available in both English and isiZulu and were hand 
delivered to patients. Ethical approval was obtained prior to commencement of this study. The 
participants were recruited by a random systematic selection by choosing every second participant. 
Both verbal and written consents were obtained before handing out questionnaires for participation. 
Statistical Package for Social Sciences (SPSS®) version of 25 was used to capture and analyse 
data. Categorical measurements were summarised using frequencies and proportions. Out of 200 
questionnaires, a total of 174 patients responded, which delivered an 87% response rate. Of the 174 
respondents, 55% (n=96) were females and 45% (n=78) were males. About 8% (n=13) of 
respondents were aware of ADRs, 55% (n=94) of drug–drug interactions and 12% (n=20) had 
reported ADRs. About 13% (n=22) respondents reported having hypertension, 7% (n=4) 
respondents reported diabetes and 1% (n=2) respondents reported tuberculosis. Almost 65% 
(n=114) respondents took the fixed drug combination, 17% (n=30) respondents took lamivudine 
and zidovudine combination, and 2.3% (n=4) respondents took ritonavir and atazanavir 
combinations. About 5% (n=8) respondents experienced vomiting, 1.7% (n=3) of respondents 
experienced diarrhoea and 1.1% (n=2) respondents experienced rashes. Most patients on ARVs and 
anti-TB medicines can experience reduced hearing or deafness, particularly in patients using 
medicines such as Kanamycin. Most medicines metabolised by CYP450, such as rifampicin and 
lopinavir/ritonavir combination, where rifampicin lowers ritonavir blood serum levels therefore 
requiring a boost of ritonavir. Patients should therefore be made aware of ADRs of ARVs, 
particularly those that may arise due to drug-drug interactions among the patients that have co-
existing diseases. Patients should also be counselled to report ADRs, to obtain the ADR form, 
complete it and ensure they submit the ADR reports the healthcare professionals as well as the 
pharmacovigilance centre. The awareness of ADRs among patients taking ARVs could be 
improved by providing quality training and in-depth counselling of the patients during their visit to 











INTRODUCTION TO THE STUDY 
 
1.1 Introduction 
Given the high prevalence of Human Immuno-deficiency Virus (HIV) in South Africa, more 
than 3 million people were reported to be using antiretrovirals (ARVs) in 2015. The figure 
escalated by about 20% within 4 years, signifying an increase in the use of ARVs by people 
living with HIV (Joint Uited Nations Programme on HIV/AIDS, 2019). South Africa has the 
highest rate of HIV positive people on antiretroviral therapy (ART) (Masenyetse et al., 2015).  
The test to treat strategy has been implemented worldwide to eliminate HIV by commencing 
positive patients on ARV medication, irrespective of patients’ CD4 count or clinical stage ( 
Davis et al., 2012; Miller et al., 2012; UNAIDS, 2019). A recent cohort study determined that 
the time to event models leading to adverse drug reaction (ADR) in HIV positive patients taking 
ART (37%) showed that patients had experienced at least one ADR (Masenyetse et al., 2015).  
Gastrointestinal, central nervous system (CNS) and dermatologic ADRs are seen in patients 
taking ARVs. Gastrointestinal reactions range from diarrhoea and nausea to hepatotoxicity. 
CNS reactions range from headaches and dizziness to neuropsychiatric disorders. Dermatologic 
reactions include rashes and skin changes. Steven Johnsons Syndrome (SJS) is an example of 
a severe dermatologic ADR due to the administration of Nevirapine (Patel et al., 2012). Since 
drug hypersensitivity reactions are a clinical problem for both health care and industry, one can 
only imagine where that leaves a patient who is completely unaware of ADRs (Pirmohamed et 
al., 2015). ADRs associated with the use of ARVs increase chances of worsening the patient’s 
condition as seen with immune reconstitution inflammatory syndrome (Abah et al., 2019; 
Murphy et al., 2007). The study investigated patient’s awareness, attitudes, and experiences of 
ADRs to antiretrovirals through a series of questions. Most studies have focused more on 
awareness of adverse drug reactions and reactions amongst healthcare professionals 
(Bogolubova et al., 2018) (Fadare et al., 2011), while a few studies have focused on patients 
awareness, attitudes and experiences (Sales et al., 2017). The study focused on patients and 
their awareness attitudes and experiences and compared its findings to literature that has already 
been published. 
 
1.2 Background to the Study 
The World Health Organisation (WHO) and other researchers define ADR as ‘a response to a 
drug which is noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis and therapy of disease, or modification of physiological function’ 
(Davies et al., 2010)(Edwards & Aronson, 2000). Cao et al,2015 and other studies  further state 





dose and in the correct manner for an appropriate indication(Cao et al., 2015) (Maddison & 
Page, 2008)(Shatz & Weber, 2015). 
ADRs are a major cause of iatrogenic morbidity, mortality and economic impact (Plumpton et 
al., 2016). Susceptibility to ADRs is influenced by age, gender, disease states, pregnancy, 
ethnicity and polypharmacy (Kaufman, 2016). Colliding epidemics of infectious non-
communicable diseases, prevalent pharmacogenetic variants associated with increased risk of 
ADRs as well as the widespread concomitant use of traditional remedies potentially contribute 
to the burden of drug-related harm (Mouton et al., 2016).  
ADRs are a major problem in clinical practice and drug development with a suggested estimate 
of 6.5%–6.7% of hospital admissions or acute hospitalisations due to them (Pirmohamed et al., 
1998)(Walker et al., 2014) 
 
1.2.1 Classification of adverse drug reactions 
ADRs were initially classified as two major subtypes: Type A (augmented) and Type B 
(bizarre). More classifications were added as Type C (chronic), Type D (delayed), Type E 
(withdrawal) and Type F (unexpected failure of therapy). Type A ADRs are augmented, 
common and are predictable from the known pharmacology of the drug ( Edwards & Aronson, 
2000; Maddison & Page, 2008). Table 1.1 presents the summarised classifications of ADRs.  
Type A reactions account for over 80% of all ADRs with the majority (70%–80%) caused by 
predictable, non-immunologic effects while Type B reactions are uncommon and 
unpredictable, dose-independent and affect a small portion of the population (Maddison & 
Page, 2008).  
 
Table 1. Classification of adverse drug reactions  
Type of reaction         Mnemonic Features  
A: Dose-related Augmented • Common 
• Predictable 
• Low morality 
• Related to drug pharmacology 
B: Non-dose-related Bizarre • Uncommon 
• Unpredictable 
• High mortality 






C: Dose-related and 
time-related 
Chronic • Uncommon 
• Related to cumulative dose 
D: Time-related Delayed • Uncommon 
• Usually dose-related 
• Occurs or becomes apparent 
after prolonged drug usage 
E: Withdrawal End of use • Uncommon 
• Occurs soon after withdrawal of 
the drug 
F: Unexpected 
failure of therapy 
Failure • Common 
• Dose-related 
• Often cause by drug interactions 
Source: Edwards and Aronson (2000) 
 
1.2.2 Drug–drug iinteractions 
Drug–drug interactions (DDIs) are one of the causes leading to ADRs (Bucşa et al., 2013). 
DDIs occur when one drug may alter the intended pharmacologic intensity and effects of 
another drug when given concurrently (Mutebi et al., 2013). Drug-related factors, such as 
polypharmacy, increase the likelihood of DDIs causing ADRs (Alomar, 2014). An adjustment 
of drug doses for infants and geriatrics is required due to their underdeveloped systems or the 
decreasing functionality of their organs, respectively.  
Health education and counselling are tools that can be used to combat factors that affect DDIs 
and ADRs (Alomar, 2014). People are at risk are the elderly, especially those taking up to four 
or more medications (i.e. polypharmacy) have a 50% chance of experiencing DDIs (Bucşa et 
al., 2013).  
 
1.2.3 The burden of adverse drug reactions related to HIV in South Africa 
According to Mouton et al. (2016), limited data on the burden of serious ADRs in sub-Saharan 
Africa, which has a high prevalence of HIV, exists. However, through the expansion of HIV 
and tuberculosis (TB) treatment programmes, the understanding of the burden of ADRs is 
improving; approximately 12 medical admissions are due to ADRs and ADRs account for 16% 
of deaths among adult medical admissions in South Africa (Mehta et al., 2017). The nature and 
frequency of ADRs in South Africa differ significantly from other countries; the population 





(Mehta et al., 2017; Mouton et al., 2016). 
 
1.3 Problem Statement 
According to HIV/AIDS statistics reported for South Africa, KwaZulu-Natal Province (KZN) 
remains the highest rated province for HIV/AIDS cases in South Africa (National Department 
of Health, 2015). ARV medicines were made available to the South African public in 2004 for  
the treatment of HIV/AIDS and related cases (National Department of Health, 2003). ARV 
medicines are provided after people have undergone testing and counselling by appropriately 
trained health personnel and have been found to be HIV positive. Since 2004, the treatment 
regimens have changed due to adverse effects, drug interactions (DIs) and resistance to ART 
(Collins et al., 2016; Njuguna et al., 2013).  
Studies in South Africa and other countries such as Switzerland have shown that ARVs have a 
number of well-recorded side effects, which result in patients’ drug regimens having to be 
changed (Kovari et al., 2013; Mouton et al., 2015). Changes in drug regimens may lead to drug–
drug interactions, causing ADRs as well as HIV/AIDS-related deaths due to the new drug 
treatments (Abo et al., 2015; Birbal et al., 2016; Mouton et al., 2015).  
Patients taking ARVs may also be taking other medicines unavoidably because of their existing 
diseases such as diabetes, hypertension, and tuberculosis. When medicines are taking at the 
same time as ARVs, there is a possibility of DDIs. Several interactions between ARVs and 
other medicines have been reported to cause ADRs (Kovari et al., 2013; Rathbun & Liedtke, 
2011; Tseng & Foisy, 2012).  
It has also been reported that many patients do not know about ADRs, particularly those caused 
by DDIs (Mouton et al., 2015). In fact, patients cannot identify the drugs that interact with other 
drugs that can result in ADRs. Studies have also indicated that patients taking ARVs can suffer 
ADRs that are caused by DDIs (Kigen et al., 2011; Miller et al., 2012). Therefore, patients need 
to be aware of drugs that interact with others causing ADRs. It is imperative that patients who 
experience ADRs can report them as this will ensure the safety of medicine use, particularly in 
patients on ARV. Therefore, in order to add to the literature on ADRs of ARVs, particularly 
among patients in public health sectors of South Africa, this study focused on awareness, 
attitudes and experiences of ADRs among patients taking ARVs.  
 
1.4  Research Questions 
The main question in this study is “what are the awareness, attitudes and experiences due to 
adverse drug reactions due to antiretrovirals and non-antiretroviral medicines among patients 
at a public health facility in KZN”? 
 





1. To what extent are patients aware of ADRs to ARV and other non-ARV medicines? 
2. What is the extent of patients’ awareness of drug interactions that result in ADRs?  
3. What are the experiences of patients regarding ADRs that result from their ARVs and other 
medicines?  
4. What are the attitudes of patients towards ADRs resulting from ARVs and other medicines?  
 
1.5 Aim and Objectives 
1.5.1 Aim  
To investigate the awareness , attitudes  and experiences towards adverse drug reactions due to 
antiretrovirals among HIV patients  at a public health facility in KZN.  
 
1.5.2  Objectives 
The study was guided by the following objectives: 
1. To establish the awareness of patients regarding ADRs of ARVs and other medicines. 
2. To determine the awareness of patients regarding drug interactions that result in ADRs 
among patients taking ARVs and other medicines.  
3. To describe patients’ experiences of ADRs of ARVs and other medicines. 
4. To determine patients’ attitudes towards ADRs of ARVs and other medicines. 
 
1.6 Research Methodology 
1.6.1 Study site and population 
The study was conducted at a public district hospital in the eThekwini Municipality in KZN. 
The hospital has an HIV/AIDS clinic, which provides services to people who are referred from 
tertiary hospitals within their catchment area and to walk-ins. Nurses, doctors, counsellors, 
dieticians and pharmacists staff the clinic. Patients are initiated for ARV on site when they are 
seen by the doctors, nurses, and counsellors.  
 
1.6.2 Study sample and size 
The sample size was calculated from the total population of patients at the study facility.  The 
following statistical parameters were used to determine sample size: a statistical power of 80%, 
effect size = 0.25, type 1 (α) error = 0.05 (this is the probability of falsely rejecting the null 
hypothesis of 5%), type 2 (β) error = 0.2 (this is the probability of falsely failing to reject the 
null hypothesis of 20%), statistical power (1- 𝛽) = 0.8 (80%). Based on the above statistical 






1.6.3 Inclusion and exclusion criteria 
1.6.3.1 Inclusion criteria 
All patients who fulfilled the following criteria were included: 
• Patients who consented to participate 
• Those who were 18 years and older 
• Those who were collecting their own medication 
• Those who were literate in isiZulu and/or English 
1.6.3.2 Exclusion criteria 
All patients who fell in the categories listed below were excluded: 
• All patients who did not consent to participate  
• Those who were below the age of 18 years  
• Patients whose families, friends or supporters were collecting their medicines on their behalf 
• Patients who were not literate in isiZulu and/or English 
 
1.6.4 Data collection process 
Data were collected through self-administered questionnaires. Three areas where patients could 
be informed about the study were identified as the main waiting room and two separate waiting 
rooms outside the nurses’ rooms. Two nurses were informed and trained about the study, and 
then assisted with data collection. There is one main waiting room and two smaller waiting 
rooms leading to the nurses rooms. Patients seated and waiting for consultation in the nurse’s 
rooms were selected. Upon entering the nurses room patients were introduced to the study and 
asked if they would like to participate in it. 
 
1.6.5 Data analysis 
The responses of the participants on the coded questionnaires were captured on Excel 
worksheet, and later transferred to Statistical Package for Social Sciences (SPSS®) version 25. 
The data was then analysed, and categorical measurements were summarised using frequency 
distribution tables and proportions. 
 
1.6.6 Ethical considerations and confidentiality 
An information leaflet clearly outlining the nature of the study and the consent of the 
participants to join the study was made available to all the participants. Participants had to 
clearly indicate if they were willing to be a part of the study by signing the consent form 
(Appendix B). Participation was completely voluntary, and no patients were coerced into 
participating in the study. Patient confidentiality was maintained throughout the study. No 





patient names. The study was approved by the Humanities and Social Sciences Research Ethics 
Committee (HSSREC) with a letter referenced HSS/2120/017M. 
 
 
1.7 Thesis Overview 
Chapter one describes the introduction, problem statement, methodology, design, and 
definitions used in the study. It also highlights the aims and objectives of the study. Chapter 
two provides a review of the literature that are relevant to this study. The findings emanating 
from the study were presented in Chapter three. The general conclusions of the study results 
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This chapter considers a variety of literature relevant to this study. Much of the literature was 
sourced on the PubMed search engine and the pertinent literature was reviewed. A review of 
studies conducted by the likes of Hamoudi et al. (2013), Mehta et al. (2017) and Mouton et al. 
(2016) indicates the need to examine the awareness, attitudes and experiences of patients 
related to ADRs and DDIs. According to a few studies by Joshi et al, (2015) and Mutebi et al,  
(2013) the use of ARV medication and other medicines is undeniable (Joshi et al., 2015)(Bucşa 
et al., 2013)(Mutebi et al., 2013). Awareness of Adverse drug reactions is discussed in a few 
studies encouraging the purpose of this  study (Nehad, 2013) (Mutebi et al., 2013)(Teka et al., 
2016). 
 
2.2 Adverse Drug Reactions  
Adverse drug reactions (ADRs) occur  when medicine causes harm to a patient with no error 
taking place, the incident is explained as an ADR that could not have been prevented (Davies 
et al., 2010).  Globally, morbidity due to adverse drug reactions accounts for 6.3%-6.7% of 
hospitalizations and mortality accounts for 0.08/100 000 - 0.12/100 000 deaths(Kaufman, 
2016)(Masenyetse et al., 2015)  (Shepherd et al., 2012). In developed countries, hospitalization 
accounts for 16.3%, mortality for 1.7% and preventable ADRs for 71.7% while in developing 
countries hospitalization, mortality and preventable ADRs account for 5.5%, 1.8% and 59.6%,  
respectively (Tarekegn et al., 2016). Honing into the developing and developed countries it was 
further reported that hospital admissions due to ADRs account for 4.2-30% in the USA and 
Canada, 5.7-18.8% in Australia, 2.5-10.6% in Europe, and 6.3% in South Africa(Sultana & 
Cutroneo, 2013)(U. Mehta et al., 2017)(Masenyetse et al., 2015). In South Africa mortality due 
to ADRs accounted for  2.5-18% (Mouton et al., 2015). Reporting of ADRs in Africa is in its 
developing stages with low numbers being reported. Africa has reported 103,499I cases in 
comparison to 11,824,804 cases reported in the rest of the world, the leading cases reported 
were ADRs due to antiretrovirals (Ampadu et al., 2016).  
  
2.3. The burden of adverse drug reactions related to HIV  in South Africa 
HIV/AIDS continues to be among the most deadly diseases ravaging the world, especially in 
sub-Saharan Africa (World Health Organization, 2015). Globally, approximately 38 million 
people were living with HIV at the end of 2019 and 1.7 million people were being newly 





According to WHO, about 2 million people living with HIV/AIDS died from illnesses related 
to Acquired Immune Deficiency Syndrome (AIDS) (World Health Organization, 2015).  
Midyear population statistics for 2018 in South Africa estimated that 56.52 million people were 
living within the country (Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020); 
approximately 7.96 million of these people (19.07%) were living with HIV (Statistics South 
Africa, 2019)(Joint Uited Nations Programme on HIV/AIDS, 2019). It has been further 
reported that more than 3 million people (42.5%) were using ARV medicines (Statistics South 
Africa, 2019). 
According to Mouton et al. (2016), limited data exist on the burden of serious ADRs in sub-
Saharan Africa, which has a high prevalence of HIV. However, through the expansion of HIV 
and TB treatment programmes the understanding of the burden of ADRs is improving; 
approximately 12 medical admissions due to ADRs account for 16% of deaths among adult 
medical admissions in South Africa ( Mehta et al., 2017).  
Mehta and colleagues explain that the nature and frequency of ADRs in South Africa differ 
significantly from other countries; the population structure, burden of disease and the risk 
profile of commonly used drugs influence this trend (Mehta et al., 2017; Mouton et al., 2016).  
Adverse drug reactions such as gastrointestinal disorders, nervous system disorders and 
psychiatric disorders, are known to be caused by DDI’s leading to hospitalization (Mirosevic 
Skvrce et al., 2011) (Bucşa et al., 2013).   
 
2.3.1 Drug–drug interactions 
Drug-drug interactions are one of the leading causes of ADRs (Bucşa et al., 2013). Drug-drug 
interactions  occur when a drug  alters the intended pharmacologic intensity and effects of 
another drug when given concurrently (Mutebi et al., 2013). Drug-related factors, such as 
polypharmacy, increase the likelihood of DDIs causing ADRs (Alomar, 2014). An adjustment 
of drug doses for infants and geriatrics is required due to their underdeveloped systems or the 
decreasing functionality of their organs, respectively.  
Health education and counselling are tools that can be used to combat factors that affect DDIs 
and ADRs (Alomar, 2014). People who are at risk are the elderly, especially those taking up to 
four or more medications (polypharmacy); they have a 50% chance of experiencing DDIs 
(Bucşa et al., 2013).  
Drug-drug interactions are one of the commonest causes of medication error in developed 
countries, and ARV medication is among the most therapeutically risky drugs for clinical 
significant DIs (Kigen et al., 2011). The complexity of DDIs is increased because of the ARV 
agents, particularly Protease Inhibitors, Non-Nucleotides Reverse Transcriptase Inhibitors and 
the CCR5 antagonists. Maraviroc, can cause or be affected by alterations in the activity of the 





Maat et al., 2003; Kigen et al., 2011).  
 
2.4 Awareness of Adverse Drug Interactions in Patients Taking Antiretrovirals 
The failure of patients to maintain a sense of constant awareness when using medicines can be 
detrimental and could have potentially fatal consequences (U. C. Mehta, 2011). Becoming more 
informed and engaged, patients can decrease the likelihood of experiencing medication errors 
and so avoid DDIs (Mutebi et al., 2013).  
A study in Ajiman, United Arab Emirates, reported that the participants had a fair knowledge 
of DIs and their types, however, most were unaware of the possible interactions between 
prescribed medications as well as how to manage and prevent DIs when they occurred (Nehad 
et al, 2013). Creating awareness about ADRs and DDIs is crucial in preventing drug-induced 
diseases and educating patients to minimise and manage them (Nehad et al., 2013)(Masenyetse 
et al., 2015)(Mutebi et al., 2013)(Teka et al., 2016). 
 
2.4.1 Antiretrovirals and their adverse drug reactions 
Despite the availability of ART and the simplification of treatment options, side effects 
continue to affect people living with HIV (Seth, 2008). In a study in south-west Nigeria, patients 
showed a considerable lack of awareness about the short- and long-term side effects of ARVs 
(Desalu et al., 2013).  
According to Reust (2011), there are several interactions between ARVs and other medications 
that can result in sub-therapeutic or supra-therapeutic concentrations (Rathbun & Liedtke, 
2011). ARVs are divided into four classes:  
a. Non-nucleoside/non-nucleotide reverse transcriptase inhibitors (NNRTIs)  
b. Nucleoside reverse transcriptase inhibitors (NRTIs) 
c. Protease inhibitors (PIs)  
d. Integrase strand transfer inhibitors (INSTI) 
Non-nucleoside reverse transcriptase inhibitors and PIs are prone to DDIs, as they are both 
metabolised by cytochrome P450 (CYP450) (Reust, 2011); this is a system prone to 
pharmacokinetic interactions (Pau & Boyd, 2010).  
 
a. Nucleoside and nucleotide reverse transcriptase inhibitors  
NRTIs are the pillars of ART. Their adverse effects are associated with lactic acidosis and 
lipodostrophy (Reust, 2011). These adverse effects present to patients in the form of fatigue, 
nausea, vomiting, abdominal pains, diarrhoea and uneven fat distribution.  
 
b. Non-nucleoside/nucleotide reverse transcriptase inhibitors 





to neuropsychiatric disorders, rash and lipid disorders (Reust, 2011). Patients with co-morbid 
psychiatric disorders are contraindicated to use Efavirenz, due to its associated hepatotoxicity 
and resultant liver failure in women with a baseline CD4 cell count of more than 250 mm3 and 
in men of more than 400 mm3 (National Department of Health, 2015). 
 
c. Protease inhibitors 
PIs are metabolised by CYP450. They are prone to cause gastrointestinal effects, 
lipohypertrophy, glucose intolerance or diabetes mellitus and lipid disorders (Reust, 2011). 
They manifest themselves in the form of diarrhoea, abdominal pains, excessive thirst, frequent 
urination, constant hunger, and weight gain. 
 
d. Integrase strand transfer inhibitors 
Raltegravir is the first drug in this class to be approved for treatment in both treatment-naïve 
and treatment-experienced patients. Raltegravir, in comparison to Efavirenz, has fewer central 
nervous and neuropsychiatric problems (He et al., 2015). However, resistance to Raltegravir 
develops easily and this limits its long-term effectiveness. Common side effects experienced 
by patients are headache, nausea, vomiting, diarrhoea, insomnia, and fatigue. 
 
2.4.1.1 Regimen combinations 
An HIV regimen is composed of ARVs used to treat HIV infection. Regimens are grouped from 
first line therapy to specialist-initiated therapy. According to WHO, the antiretroviral regimen 
has been consolidated to accommodate most countries to have the same regimen and seen 
globally and in Zimbabwe and South Africa (Hirnschall et al., 2013)(Ministry of Health and 
Child Care, 2018)(South African National Department of Health, 2015).  
 
2.4.1.2 Drug–drug interactions among antiretroviral classes 
ARV medicine from the same class is generally avoided with the exception of approved NRTIs 
and Ritonavir boosting for other PIs (Foy et al., 2014). NNRTIs and PIs are metabolised by 
CYP450, causing interactions with these classes and other ART metabolised by CYP450 
(Reust, 2011). PIs are primarily metabolised by CYP3A4 and are substrates for p-glycoprotein, 
while NNRTIs are substrates of CYP2B6 and/or CYP3A4 (Rathbun & Liedtke, 2011).  
Regimens composed of both PIs and NNRTIs are generally avoided due to evident interactions. 
INSTI generally exhibits fewer interactions with other ART, as it is metabolized by uridine 






2.4.1.3 Drug interactions between antiretrovirals and non-antiretrovirals  
Various medications commonly used in primary care settings can exhibit an altered mechanism 
when used with ARV drugs (Rathbun & Liedtke, 2011). Many patients require additional 
medication to manage ARV associated adverse effects, such as hyperlipidemia and other co-
morbidities (hypertension, diabetes mellitus and tuberculosis) (Pau & Boyd, 2010). DDIs and 
other medication can occur through various mechanisms. Medication such as Metformin and 
Isoniazid metabolised by CYP450 can potentially interact with PIs and NNRTIs (Ogu & Maxa, 
2000; Rathbun & Liedtke, 2011). 
 
2.4.1.4 Healthcare professionals’ and traditional health practitioners’ knowledge 
regarding drug–drug interactions and adverse drug reactions 
Most studies have questioned whether healthcare professionals are knowledgeable about DDIs 
and can counsel patients appropriately when patients purchase medicinal products (Ansari, 
2010)(Gilligan et al., 2011)(Harrington et al., 2011). Many drugs are introduced annually, thus 
making it impractical for physicians to rely on memory alone to avoid potential drug 
interactions (Ansari, 2010). Clinicians in resource-limited countries see high volumes of 
patients, have limited reference resources and thus find it difficult to avoid, detect and manage 
drug interactions (Pau & Boyd, 2010). However, as guardians of patients’ health and safety, 
healthcare professionals have a responsibility to identify and prevent ADRs, making it essential 
that those who prescribe and dispense medications are educated and knowledgeable about 
DDIs, their potential to produce ADRs and the subsequent negative patient-related outcomes 
(Harrington et al., 2011). 
One study states that physicians discuss what patients want to hear and not the actual or 
potential side effects patients may experience (Wylie et al., 2015). Informing patients about 
DDIs causing side effects and ADRs may result in doing more good than harm (Wells et al., 
2013). Ethically, patients need to know the truth about the medication they are taking. Doctors 
are the first treatment initiators and therefore should inform patients about the possible side 
effects from the drugs they have been prescribed. Pharmacists can also ensure the safe, 
appropriate and effective use of medication and counsel patients on side effects when they 
dispense medication (Iancu et al., 2015). 
DDIs during ART are common and often require dose modification to mitigate unwanted 
adverse events and sustain therapeutic concentrations (Rathbun & Liedtke, 2011). Awareness 
of the most commonly occurring DDIs should be raised to assist healthcare workers to prevent 
DDIs and ADRs (Bucşa et al., 2013). Although most HIV clinicians are aware of potential 
DDIs, many find themselves lacking the knowledge to recognise and manage interactions with 





Traditional health practitioners selected from two urban and rural areas in KZN were trained 
and encouraged to help reduce the risk of practices and to provide appropriate information and 
referral for their patients to consult doctors (Busia, 2010). Traditional healthcare providers 
should play a role in counselling patients appropriately about the potential of DDIs to cause the 
possibility of ADRs. People select the medicinal products of traditional healers, disregarding 
their doctor’s advice on conventional medicines, and these products potentially lead to 
interactions with other pharmaceuticals. If doctors could become allies with traditional healers, 
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Awareness, attitudes, and experiences of patients taking antiretrovirals towards adverse drug 
reactions at a public health facility in KwaZulu-Natal 
Abstract 
Background: Adverse drug reactions (ADRs) are undesirable side effects that occur even when a drug 
is administered at the proper dose and correctly for an appropriate indication. Given the high prevalence 
of HIV in South Africa, more than 3 million people are reported to be taking antiretrovirals (ARVs). 
There is co-morbidity of diseases such as HIV/AIDS with other diseases including tuberculosis, 
diabetes, and hypertension, which inevitably may lead to polypharmacy, therefore increasing the risk 
of ADRs. Patients taking ARVs should be aware of the ADRs that may occur in ARV therapy. 
Aim: This study aimed to investigate patients' awareness, attitudes, and experiences of ADRs that are 
precipitated by ARV therapy. 
Setting: The study was conducted at a public hospital in KwaZulu-Natal, in South Africa. 
Method: This was a descriptive cross-sectional study using a self-administered questionnaire which 
contained close-ended questions to which patients responded. Questionnaires were available in both 
English and isiZulu and were hand delivered to patients.  
Results: Out of 200 questionnaires, a total of 174 patients responded, which delivered an 87% response 
rate. Of the 174 respondents, 55%(n=96) were females and 44%(n=78) were males. About 8%(n=13) 
of respondents were aware of ADRs, they were followed by 9% (n=15) who had experienced them, and 
only about 12%(n=20) had reported on them. About 8% (n=13) of respondents were aware of ADRs, 
55% (n=94) of drug–drug interactions and 12% (n=20) had reported ADRs. About 13% (n=22) 
respondents reported hypertension, 7% (n=4) respondents reported they were diabetic, and 1% (n=2) 
respondents reported they had tuberculosis. Around 65% (n=114) respondents were taking the fixed 
drug combination, while 17% (n=30) were on the lamivudine and zidovudine combination and only 
2.3% (n=4) respondents were on ritonavir and atazanavir combinations. About 5% (n=8) respondents 
experienced vomiting, 1.7% (n=3) of respondents experienced diarrhoea and 1.1% (n=2) respondents 
experienced a rash.  
Conclusion: The awareness of ADRs among patients seemed exceptionally low and needs to be 
improved by conducting training and in-depth counselling of the patients at each visit to the hospital. 
Patients need to be aware that ADRs should be reported to their healthcare professionals about the side 
effects of drug interactions they experience. 
 










According to HIV/AIDS statistics for South Africa, KwaZulu-Natal Province (KZN) remains the 
highest rated province for HIV/AIDS cases in South Africa (NDoH, 2015; Statistics South Africa, 
2018). Despite the availability of ART and the simplification of treatment options, ADRs continue to 
affect people living with HIV (Seth, 2008). Adverse drug reactions (ADRs) are undesirable side effects 
that occur even when a drug is administered at the proper dose and correctly for an appropriate 
indication (Cao et al., 2015).  
Since 2003, ART regimens have changed due to adverse effects, drug interactions and resistance to 
ARV therapy (Collins et al., 2016; Njuguna et al., 2013). Studies in South Africa and other countries 
such as Switzerland have shown that ARVs have several well-recorded side effects, which result in the 
drug regimens of patients having to be changed (Kovari et al., 2013; Mouton et al., 2015). Changes in 
drug regimens may lead to drug–drug interactions (DDIs), causing ADRs as well as HIV/AIDS-related 
deaths due to the drug treatments (Abo et al., 2015; Birbal et al., 2016; Mouton et al., 2015). 
According to a study done in India it was reported that the awareness of ADRs in patients is limited 
(Joshi et al., 2015). A study in south-west Nigeria reported lack of awareness about the short- and long-
term side effects, which are secondary unwanted effects from a drug and, different from ADRs which 
are unwanted or unintended reaction occurring during drug therapy (Desalu et al., 2013). It seems as 
though patients are more accustomed to the term side effects and not ADRs which may be the reason 
for the lack of  awareness regarding  ADRs. However, by examining patient records, studies in Saudi 
Arabia and South Africa have shown that patients have experienced ADRs (Mehta et al., 2017; Sales et 
al., 2017) although it may not have been reported by patients themselves but healthcare professionals. 
In countries such as Sweden, Canada and Denmark systems are in place that enable patients to 
spontaneously report ADRs. Most countries in Africa, including South Africa, have a long way to go 
to achieve this type of support (Van Hunsel et al., 2012)(Maigetter et al., 2015). However, in some 
studies attitudes towards reporting ADRs have been demonstrated to be low irrespective of systems that 
are in place (Mehta et al., 2017)(Sales et al., 2017). 
 
Aim and Objectives 
This study aimed to investigate whether patients taking ARVs in a public health facility in KZN are 
aware of ADRs; and to determine the experiences and attitudes of patients towards these ADRs. The 
study was guided by the following objectives: 
1. To establish the awareness of patients regarding ADRs of ARVs and other medicines. 
2. To determine the awareness of patients regarding drug interactions that result in ADRs. 
3. To describe patients' experiences of ADRs caused by their ARVs and other medicines. 







Research Methods and Design 
 
Study design  
This study is a descriptive cross-sectional quantitative study using a questionnaire survey to obtain 
relevant information from participants. The self-designed structured questionnaire was used to collect 




The study was conducted at Clairwood Hospital, which is a district hospital in the eThekwini 
Municipality in KZN. The hospital has an HIV/AIDS clinic which provides services to people who are 
referred from tertiary hospitals within their catchment area and to walk-ins. Nurses, doctors, 
counsellors, dieticians, and pharmacists staff the clinic. Patients were initiated for ART on site when 
they have been seen by doctors, nurses, and counsellors.  
 
Study Sample and Size 
The sample size was calculated from the total population of patients at the study facility. The following 
statistical parameters were used to determine the sample size: a statistical power of 80%, effect size = 
0.25, type 1 (α) error = 0.05 (this is the probability of falsely rejecting the null hypothesis of 5%), type 
2 (β) error = 0.2 (this is the probability of falsely failing to reject the null hypothesis of 20%) and 
statistical power (1- 𝛽) = 0.8 (80%), calculated using Raosoft®, 2017. Based on the above statistical 
parameters, a minimum sample size of 180 was determined.  
 
Inclusion and Exclusion Criteria 
Inclusion criteria 
All patients who fulfilled the following criteria were included: 
▪ Those who consented to participate 
▪ Those who were 18 years and older  
▪ Those who were collecting their own medication  
▪ Those who were literate in isiZulu and/or English 
Exclusion criteria 
All patients who fell in the categories listed below were excluded: 
▪ All patients who did not consent 
▪ Patients who were under the age of 18 years  
▪ Patients whose families, friends or supporters were collecting their medicines on their behalf 






Data Collection Process 
Data were collected using self-administered questionnaires. Three places where patients could be 
informed about the study were identified: the main waiting room and two separate waiting rooms 
outside the nurses’ rooms. Two nurses assisted in collecting the data. One worked with the staff and the 
other worked with patients. The terms, such as ADR and DDI, were explained to patients because these 
terms could not be successfully translated into isiZulu. 
A structured questionnaire was developed and administered to the participants, and consisted of four 
main sections:  
A.  Participants’ socio-demographic characteristics 
B.  (i) Awareness of ADRs; and 
  (ii) Awareness of drug interactions leading to ADRs  
C.  Experiences of ADRs caused by ARVs and other medicines 
D.  Attitudes towards ADRs caused by ARVs and other medicines.  
 
Data Analysis 
Data were analysed using SPSS version 25. Frequency variables were established through data input. 
Valid percentages were calculated, and the report compiled. 
 
 Ethical Considerations and Confidentiality 
A consent form clearly outlining the nature of the study and the enrolment for their approval to join the 
study was made available to all the participants. Participants had to indicate if they were willing to be 
a part of the study by signing a consent form. Participation was completely voluntary, and no patients 
were coerced into participating in the study. Patient confidentiality was maintained throughout the 
study. No personal information was requested, and questionnaires were identified by numbers and not 
by patient names. The study was approved by the Humanities and Social Sciences Research Ethics 






Socio-demographic characteristics of the participants 
A total of 174 out of the 200 questionnaires issued out were completed and returned by the participants 
which gave a response rate of 87%. Of the 174 participants, 55.2% (n=96) were responded they were 
females and 44.8% (n=78) were males. The majority of the participants were in the age group 31–40 
years. Regarding the participants’ racial distribution in this study, 98.3% (n=171) responded they were 
blacks and 1.7% (n=3) were coloureds. Most of the participants 44.3% (n =77) responded that they had 
completed schooling at the primary school level and 25.3% (n=44) had completed Matric. Other levels 
of education reported by participants were as shown in Table 1. 
 
TABLE 1 
Socio-demographic characteristics of the participants (N = 174) 
Variables Number of 
participants (n) 
Percent (%) 
Age group   
21–30 years 37 21.3 
31–40 years 68 39.1 
41–50 years 48 27.6 
Above 51 years 21 12.0 
Total 174 100.0 
Gender  
Male 78 44.8 
Female 96 55.2 
Total 174 100.0 
Race   
Black 171 98.3 
Coloured 3 1.7 
Total 174 100.0 
Level of education  
Primary school 77 44.3 
Matric 44 25.3 
Diploma 16 9.2 
Bachelor 3 1.7 
Certificate 32 18.4 












 Key: * indicates data was missing due to participants who did not report on employment status 
 
Awareness of participants regarding ADRs of ARVs  
Of the 174 participants who were asked if they were aware of ADRs of ARVs, 98.8% (n=172) 
responded to the question (Table 2). Of those who responded to the question, only 13 (7.6%) participants 
said “Yes”, they were aware of ADRs of ARVs.  Of the 174 participants who were asked if they were 
aware of DIs causing ADRs, 97.7% (n=170) responded to the question. Of those participants, about 
55% (n=94) agreed that they were aware of DIs causing the ADRs of ARVs (Table 2). In addition, 
participants were asked about the types of DIs causing ADRs, and all the 174 participants responded 
except for one participant who did not respond regarding drug-drug interactions (Table 2).  About 32% 
(n=56) of participants agreed that they were aware of drug-herb interaction and other participants also 
reported awareness of other types of DIs as shown in Table 2.  
Further, an alarmingly high proportion of participants (n= 153, 93.9%) were not aware of what causes 
ADRs. With regards to what causes ADRs, the participants were asked to choose between “taking other 
medication with ARV”, “eating certain foods with ARV”, “taking herbs with ARV” as well as 
“medication overdose”. Of the 174 participants, only 9.2% (n=16) recognized ARV-herb interaction 
(AHI)  due to taking herbs with ARV as a cause of ADR, and 2.3% (n=4) agreed to medicine overdose 





Total 174 100.0 
Employment status   
Unemployed 84 48.3 
Employed 87 50.0 
Missing data* 03 1.7 
Total 174 100.0 
Diagnosis  
HIV 174 100 
Diabetic 7 4.0 
Hypertension 22 12.6 
Tuberculosis 2 1.1 
Cholesterol 7 4.0 





 TABLE 2 
Participants’ awareness about ADRs and DIs of ARVs  
 Frequency Percentage 
 n % n % 
Statement Yes No 
  N % N % 
Are you aware of ADRs? (n=172)* 13 7.6 159 92.4 
Are you aware of DIs? (n=170)* 94 55.3 76 44.7 
Types of drug interactions     
Drug–drug interactions (n=173)* 26 15.0 147 84.5 
Drug–food interactions (N=174) 16 9.2 158 90.8 
Drug–herb interactions (N= 174) 56 32.2 117 67.2 
Drug–disease interactions (N=174) 14 8.1 160 91.9 
Key: * indicates data was missing due to participants who did not respond to the question 
 
Attitudes and experiences of participants regarding ADRs of ARVs 
Of the 174 participants in this study, about 95% (n=166) responded to the statement on “have you 
experienced any ADRs?”. Of those who responded to the statement, 9% (n=15) reported that they had 
experienced ADRs. Some of the participants who experienced ADRs reported vomiting (n=8, 4.6%), 
and diarrhoea (n=3, 1.7%), both of which were the commonly reported gastrointestinal ADRs as seen 
in Table 3. About 12% (n=20) of the 167 participants who responded to “Have you reported an ADR?” 
agreed to have reported an ADR. This shows that many of the participants do not report the ADRs they 
experienced from their ARVs. The participants mainly reported to the nurses and very small proportion 
reported ADR to the pharmacists.  
About 8% (n= 14) of the participants reported that they received counselling on ADR as shown in Table 
3. The pharmacy department was mostly chosen as where ADRs can be reported by 7% (n=12) of the 
172 participants who responded to the question (Table 3).  
 
TABLE 3 
Participants’ attitudes and experiences regarding ADRs of ARVs.  
Statements Yes No                           
 N % N %      
Have you experienced an ADR? (n=166)* 15 9 151 91         





Kidney failure 1 0.6 173 99.4      
Low CD4 count 1 0.6 173 99.4   
Rash 2 1.1 172 98.9 
Diarrhoea 3 1.7 171 98.3 
Vomiting 8 4.6 166 95.4 
Unexplainable weight gain 1 0.6 173 99.4 
Dizziness 1 0.6 173 99.4 
Have you reported an ADR? (n=167)* 20 12 147 88 
How often?     
Weekly  (n =173)* 0 0 173 100 
Monthly (n=173)* 0 0 173 100 
Few times a year (n=173)* 21 12.1 152 87.9 
Never (n=173)* 3 1.7 170 98.3 
To whom did you report it?     
Nurse (n=172)* 16 9.3 156 90.7 
Doctor (n=173)* 10 5.8 163 94.2 
Pharmacist (n=172)* 3 1.7 169 98.3 
What happened after you reported? (n=173)**     
ADR form was completed 3 1.7 170 98.3 
Counselling 14 8.1 159 91.9 
Medication was changed 2 1.2 171 98.8 
Nothing was done 2 1.2 171 98.8 
Where do you think ADRs can be reported? 
(N=174) 
    
Pharmacy department (n=172)* 12 7.0 160 93.0 
MCC** (N=173)* 2 1.2 171 98.8 
Drug company (N=173)* 2 1.2 171 98.8 
Department of Health (N=173)* 5 2.9 168 97.1 
     
Key: * indicates data was missing due to participants who did not respond to the question ; ** The medicine control 




The study included both males and females and most of the participants were aged 31–40 years. The 
majority of the participants were blacks (98.3%, n=171) and others were coloured (1.7%, n=3). There 





South Africa and this could be due to the site at which the study was conducted. Over 40% of 
participants had not completed their schooling and had dropped out of schooling while in primary 
school. About 25.3% (n=44) had matriculated, some had achieved certificates in courses conducted to 
further their education and a few had proceeded to get a diploma or a bachelor’s degree. The drop out 
from schooling could be due to substance abuse, teenage pregnancy, financial constraints and other 
academic issues (Weybright et al., 2017). The study reported that almost an average number of the 
participants were unemployed. At the time the study was conducted, the unemployment rate was high 
at 29% in South Africa, according to the South African Labour Force Survey (Statistics South Africa, 
2019). However, unemployment in the study was recorded at 48.3%. Based on the total number of the 
participants, it is understandable why the rate is higher than the national unemployment rate.  
 
Awareness of adverse drug reactions in patients taking antiretrovirals 
Notwithstanding co-morbidity resulting in polypharmacy leading to DDIs and ADRs, only a low 
proportion of participants (7.6%, n= 13) were aware of ADRs of ARVs in this study (Table 2). This 
result is similar to a study reported in Nigeria (Desalu et al., 2013) but in contrast to the findings in 
Saudi Arabia where higher proportion of participants were aware of ADRs (Sales et al., 2017). Lack of 
awareness regarding ADRs is a major concern. ARVs present with ADRs, such as Steven Johnson 
Syndrome (SJS), which is a severe skin reaction that requires immediate medical attention (Chateau et 
al., 2019). If patients are not aware that a minor rash may rapidly develop into a severe condition, they 
may not report the reaction or consider it important enough to report. This increase the concerns that 
the awareness among participants was low regarding the DIs of ARVs and non-ARVs. 
Patients also lack awareness of non-ARV medicines that interact with ARVs. Awareness regarding 
ADRs or the lack thereof may result from the absence of counselling about the term “ADR”. According 
to Joshi et al 2015, a “side effect” is a term commonly used with patients more than “ADRs”, and 
suggested that the terms may be interchangeable (Joshi et al., 2015). The interchangeable use of the 
terms may therefore be a contributing factor to the lack of awareness regarding ADRs which further 
implicates the low level of awareness among the participants in this study. Interestingly, studies that 
used the term “side effects” in investigating awareness of ADRs still recorded low levels of awareness 
(Desalu et al., 2013; Sales et al., 2017). This shows that it is important to educate patients on the terms 
side effects and ADRs to increase awareness of the terms among the patients regarding their 
medications. Furthermore, a high proportion of participants were unaware of what causes ADRs. The 
lack of awareness of ADRs and the causes thereof may lead to increased hospitalisations and death of 
patients taking ARVs, which could be prevented (Mouton et al., 2015). It is therefore necessary to 
counsel patients on possible causes of ADRs to prevent fatalities, improve ART and ensure patients 
safety. 
 





There were four types of DIs that the participants were asked to identify which of them they were aware 
of. Drug–herb interactions (DHI)_were the DIs most recognised by the participants, followed by drug-
drug interactions (DDI). Although DHI was mostly recognized by the participants, however, the 
proportion of the participants who recognized the DHI was relatively low.  This study finding is similar 
to the study reported by Nehad et al 2013, where participants in their study had reported low recognition 
of DHIs (Nehad et al., 2013). The patients on ARVs may present with co-morbidities, thus their drug 
intake may increase (Kovari et al., 2013). This may increase the likelihood of the co-administration of 
herbal medicines resulting in increased drug–herb interactions (Moreira et al., 2014). It is important that 
patients know about DHIs and be counselled on them to prevent ADRs.  
Similar to the proportion of participants who recognized DHI, a relatively lower proportion of 
participants recognised DDIs. The potential of DDIs is common among elderly patients as they do 
experience DDIs when taking several medications (Teka et 2016). ,  To deal with the resulting ADRs 
due to DDIs, patients often take other medications without checking the problem of DDI when 
medicines are co-administered  with their chronic medication (Bucşa et al., 2013) Healthcare 
professionals should  do all they can to deal with ADRs due to polypharmacy  (Ansari, 2010; Bucşa et 
al., 2013; Teka et al., 2016). The low awareness of the different types of DIs leading to ADRs requires 
that drug information and drug interaction centres  be established to address the seriousness of DDIs 
and ADRs (Mutebi et al., 2013).  
Drug–food interactions (DFI) occur when food and medicine interfere with each other (Bushra et al., 
2011). A low percentage of participants (9.2%, n=16) were aware of DFIs. Drugs such as Abacavir are 
better taken on an empty stomach to increase absorption; when taken on a full stomach, absorption is 
reduced (Fadare et al., 2011). Patients need to be made aware of when to take their medicines with or 
without food. Patients with chronic kidney disease (CKD) are further compromised when taking drugs 
such as Tenofovir, because the drug are harmful to the kidneys and it will exacerbate the CKD (Muaed 
J.A. 2014). Thus, patients should be made aware that tenofovir needs to be changed to a suitable drug 
that will not further compromise the kidneys.  
Patients may not be aware of relevant health terminologies and information known by the healthcare 
professionals. It is therefore it is necessary to improve the awareness of patients regarding different 
terminologies and information in health, particularly ADRs, DDIs, DHIs, DFIs as well as drug-disease 
interactions which may create a more medically conscious and health informed community.  
 
Patients’ experiences of adverse drug reactions  
Only a small percentage of patients (9%) indicated that they have experienced ADRs. This may be due 
to patients being more aware of the term “side effects” than “adverse drug reactions” (Gupta et al., 
2015). Studies in India, Nigeria and South Africa reported that the experience of ADRs and reporting 
is low among both the healthcare professionals and patients (Abah et al., 2019; Ampadu et al., 2016; 





have investigated the most common types of ADRs experienced by patients on ART (Birbal et al., 
2016). However, based on the findings of this study, the question stands as to whether patients are aware 
of experiencing ADRs or if they thought of the ADRs as common side effects that do not require 
reporting. Patients need to be told that they are experiencing ADRs and an explanation of what that 
means and how it will be managed must be presented to the patients. For example, if patients react to 
Nevirapine and experience SJS, they need to be told which drug caused the ADRs and how it will be 
changed so that they are aware and that their adherence to their drug regimens is not compromised. 
 
Patient’s attitudes towards adverse drug reactions and ADR reporting 
The reporting of ADRs should not be left solely in the care of healthcare professionals including nurses, 
doctors, and pharmacists. Patients should be introduced to reporting ADRs and should be given access 
to the reporting system. Only 12% of patients in this study have reported ADRs. These reports were 
mainly made to nurses rather than doctors and the pharmacists. This is different to studies in Saudi 
Arabia and Nigeria which found that respondents reported their ADRs more to doctors than to nurses 
(Joshi et al., 2011; Sales et al., 2017). The reason why the participants mainly reported ADRs to the 
nurses and very small proportion reported to the pharmacists may be due to the fact that the patients 
collect medications from the nurses rather than the pharmacists.  
There are numerous ways ADRs can be reported by patients, starting with informing a doctor, a nurse 
a pharmacist or spontaneous reporting. The study showed that majority of participants did not receive 
counselling about ADRs of ARVs after they have reported them. Patients are not aware of ADR 
reporting (Sales et al., 2017) and this remains a cause for concern.  
It is undeniable that every year thousands of medications are introduced into the market (Nehad et al., 
2013). Patients who are on prescribed medication such as ARVs have access to medication which has 
not been prescribed such as over the counter medication or herbal supplements. 
Ingestion of one or multiple ARV medications may lead to undesirable side effects. Unavoidably, the 
ingestion of multiple medications due to co-morbidities increases the likelihood of patients experiencing 
undesirable effects that ultimately result in ADRs. Therefore, being aware of ADRs and their causes 
may help to minimise hospitalisations and unwarranted death. 
 
Conclusion 
This study revealed that participants’ awareness of ADRs to ARVs and other medicines was low. The 
patients’ attitudes towards reporting ADRs due to DDIs was poor, and not many patients reported 
experiences of ADRs regarding ARVs and other medicines. This may be due to lack of awareness 
regarding ADRs. It may also be due to the fact that participants could have been counselled using the 
term “side effects” more than “adverse drug reactions”. This could have resulted in participants’ lack 
of reporting ADRs they have experienced. Creating awareness about ADRs and what causes them 





posters around healthcare facilities. Patients can read the posters while waiting to collect their medicines 
which could then create awareness for them . Reporting of ADRs by patients to health care professionals 
and spontaneous reporting should be taught and encouraged. This will help to reduce the increasing 
yearly rates of morbidity and mortality due to ADRs in patients taking ARVs and other medicines. This 
study revealed the need for ADRs reporting especially among patients, which will increase 
pharmacovigilance database that will further assist in monitoring the ADRs and side effects of 
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SYNTHESIS AND CONCLUSIONS 
 
4.1 Introduction 
While several studies have assessed the knowledge and attitudes of health workers regarding ADRs, 
only few studies have investigated patients’ knowledge and attitudes about ADRs particularly while 
taking ARVs. As at the time of writing this dissertation, there has been no study found in the literature 
on awareness, attitudes, and experiences of ADRs among patients taking ARVs, particularly among 
patients at a public health facility in KwaZulu-Natal. This dissertation aimed at determining patients’ 
awareness, attitudes, and experiences of ADRs among patients taking ARVs. The study specifically 
targeted patients who were taking ARVs and possibly non-ARV medicines due to co-morbidities that 
exist among this category of patients. This chapter therefore reports on the findings that support the 
overall aim of the study conducted at the selected public hospital in eThekwini, KwaZulu-Natal, South 
Africa.  The relevant key findings were discussed in the manuscript chapter (chapter 3) that was 
prepared and is to be submitted to a journal for publication. The synthesis chapter (chapter four) further 
shows the extent to which each objective was met by briefly presenting the main findings and 
conclusions. The significance and limitations of the study were highlighted, and recommendations for 
future research and practice were provided. 
 
4.2 The study aim, objectives, and highlights of key findings 
The aim of the study was to determine the awareness of, attitudes towards and experiences of adverse 
drug reactions due to antiretrovirals among patients taking ARVs at a public health facility in KZN.  
 
4.2.1 The study objectives were: 
1. To establish the awareness of patients regarding ADRs due to ARVs and other medicines. 
2. To determine the awareness of patients regarding drug interactions that result in ADRs of ARVs 
and other medicines.  
3. To describe patients’ experiences of ADRs resulting from ARVs and other medicines. 
4. To determine patients’ attitudes towards ADRs to ARVs and other medicines. 
 
 4.2.2 The highlights of the key findings of the study  
The socio demographic characteristic of the participants 
The study reported on both males and females with the majority aged between 31–40 years. Although 





(n=96) females. Based on the site where the study was conducted, most participants were black 98.3% 
(n=171) and 1.7% (n=3) were coloured. Over 40% of participants (n=77)had not completed their 
schooling and had dropped out while in primary school; however, 25.3% (n=44) had matriculated.  
According to the Labour Force Survey in South Africa, the unemployment rate was 29% during the 
period which this study was conducted (Statistics South Africa, 2019). However, in this study, 
unemployment was 49.1%. Based on the limited total number of participants, it is notably 
understandable why the rate is higher than the national rate of unemployment. The employed 
participants included those who are self-employed and/or working part-time jobs. 
The patients taking ARVs in this study also had diabetes (4%), hypertension (12.6%), tuberculosis 
(1.1%), epilepsy (0.5%) and cholesterol (4%). This increases the possibility of numerous drugs being 
taken simultaneously and thus increases the potential of DDIs leading to ADRs.  
 
Objective 1. To establish the awareness of patients regarding ADRs due to ARVs and other 
medicines. 
Notwithstanding co-morbidity resulting in polypharmacy leading to DDIs and ADRs, a significantly 
low percentage of patients (8%) are aware of ADRs. In contrast, a study in Saudi Arabia reported a fair 
percentage of patients being aware of ADRs, while a study in Nigeria also reported a low percentage of 
awareness in patients ( Desalu et al., 2013; Sales et al., 2017). Lack of awareness of ADRs is concerning.  
The presence of ARVs with ADRs, such as SJS, increases concerns for awareness of ARV and DIs. 
Patients in this study lack awareness of non-ARV medicines that interact with ARV medications. 
Awareness regarding ADRs and the lack thereof may result from the absence of counselling and the 
knowledge of the terminology about ADRs. “Side effects” is a term commonly used with patients more 
so than “ADRs” which may be a contributing factor to the lack of awareness of ADRs (Joshi et al., 
2015). Only a few patients were aware of what causes ADRs. The lack of awareness of patients 
regarding ADRs and the causes thereof may lead to increased hospitalisations and death which could 
have been prevented (Mouton et al., 2015). Awareness of what ADRs are but not being aware of what 
causes ADRs still remains a challenge. For instance, patients taking Nevirapine are aware that it can 
cause an ADR, but might not be aware that Nevirapine causes an SJS reaction.  
 
Objective 2  To determine the awareness of patients regarding drug interactions that result in 
ADRs of ARVs and other medicines 
DDIs can result in ADRs that require hospitalisation (Bucşa et al., 2013). DDIs are one of four types of 





A low proportion of patients (15%) were aware of DDIs. It is common for patients to experience side 
effects when taking medication and to deal with those side effects without checking if they can be co-
administered with their chronic medication (Ansari, 2010; Bucşa et al., 2013; Teka et al., 2016).  
Drug–herb interactions were the highest recognised drug interactions by patients – 32% (n=55). People 
on ARVs who may present with co-morbidities increase their drug intake (Kovari et al., 2013). This 
increases the likelihood of herbal medicines being co-administered and results in increased drug–herb 
interactions (Moreira et al., 2014). In addition, most food groups consist of herbs such as garlic. Greater 
awareness of ADRs due to herbal medicine is required (Hamoudi et al.,  2013). 
Drug–food interactions occur when food and medicine interfere with each other. A low percentage of 
patients (9%, n=16) are aware of drug–food interactions. Drugs such as Abacavir are better taken on an 
empty stomach to increase absorption; when taken on a full stomach, absorption is reduced (Fadare et 
al., 2011). Increasing the awareness and better understanding of patients regarding how food interacts 
and interferes with the efficacy of their medication will assist in achieving therapeutic objectives. 
Drug–disease interactions were the lowest recognised with only 8% (n=14) of patients demonstrating 
awareness. The awareness of the different types of DIs leading to a ADRs remains low, therefore DDI 
centres should be established to address the seriousness of DDIs and ADRs (Mutebi et al., 2013). 
 
Objective 3 To describe patients’ experiences of ADRs resulting from their ARVs and other 
medicines. 
Only a small percentage of patients (9%) indicate that they have experienced ADRs. This may be owing 
to the fact that patients may be commonly aware of the term “side effects” over “ADRs” (Gupta et al., 
2015). Studies in India, Nigeria and South Africa reported lack of awareness of ADRs and the reporting 
by both healthcare professionals and patients (Abah et al., 2019; Ampadu et al., 2016; Desai et al., 
2011). Therefore, numerous patients may be experiencing ADRs more than that which is being reported. 
The most common types of ADRs experienced by patients on ART have been reported (Birbal et al., 
2016). However, based on the findings of this study, the question stands as to whether patients are aware 
that they have experienced ADRs or whether they simply brush them off as common side effects that 
do not require further investigation or reporting. 
 
Objective 4 To determine patients’ attitudes towards ADRs of ARVs and other medicines. 
Only 12% of patients have reported ADRs. There are numerous ways ADRs can be reported, such as 
informing a doctor, a nurse, a pharmacist, or spontaneous reporting by patients. Patients are not aware 





2017). Patients attitudes regarding reporting on ADRs of ARVs and other medication is low. It can be 
argued that patients do not see it necessary to report due to increased number side effects ARVs 
presented with (Van der Walt et al., 2013), therefore they probably feel it’s expected and something 
they should be able to live with considering the nature of the immune compromising virus.  
 
4.3 Significance of the study 
This study has revealed lack of patients’ awareness regarding ADRs of ARVs and other medicines. The 
attitudes towards and experiences of ADRs reporting among patients was poor suggesting the need to 
encourage ADR reporting among patients taking ARVs.  
The study also showed the need for healthcare professionals to strengthen patient education regarding 
ADRs of ARVs, as well as ADR reporting. 
 There is also a need for development of antiretroviral stewardship policies that will guide the 
monitoring and counselling of patients taking ARVs, particularly in preventing ADRs, promoting 
patient’s safety and optimizing ARV therapy. 
The findings of the study will guide the planning of educational programmes for the patients, 
particularly to create awareness about ADRs of ARVs as well as ADRs due to DDIs among patients 
with coexisting disease conditions. 
. 
4.4  Limitations 
The study was conducted in one public healthcare facility within the eThekwini district, in the KZN 
province hence the study findings cannot be generalized to all patients taking ARVs in KZN and the 
whole of South Africa.  
It was challenging to get patients to participate and consent due to the sensitivity of HIV as the disease 
condition being treated with ARVs. However, once confidentiality and anonymity were explained, 
patients were willing to give consent and participate in the study. 
The use of questionnaires could have limited the interpretation of the study findings as the study relied 
on the information that the respondents provided which could have been subjected to recall bias and the 
information could have been exaggerated during the completion of the questionnaires 
 
4.5  Recommendations 
The lack of awareness regarding ADRs in patients makes it imperative to develop a platform to increase 
patients’ awareness. Educating patients on the terms “ADRs” and “side effects” simultaneously is 
encouraged. It is important to make patients aware of how to report ADRs. Patients should be at liberty 
to express each ailment they experience when taking their ARV and non-ARV medication. Upon 





the side effects and ADRs they may experience when ingesting the medication. Upon follow-up visits, 
patients should be encouraged to express any new experiences which they experienced during the 
duration of the treatment. Patients should be made aware of spontaneous reporting systems that are in 
place. These should be made accessible and facilitate reporting irrespective of their educational level 
and language constraints of patients.  
Healthcare professionals should be reminded on the importance of counselling patients each time they 
consult them and monitor patients’ adherence to medication. The pharmacists could establish 
antiretroviral use monitoring whereby follow-up protocol is designed for checking how patients are 
progressing since their last appointment, identify any misunderstandings to their treatments and make 
further assessments during patients’ visits to the health facilities. 
Similar studies should be conducted across other health districts in South Africa in order to understand 
the status of ADRs awareness and ADRs reporting among patients ARVs. Such studies may be extended 
to both private and public healthcare facilities. The risk of the possible DDIs among patients who are 
taking ARVs as well as other medicines due to their co-existing diseases could be investigated.  
 
4.6 Overall Conclusion 
This study revealed that participants awareness of ADRs to ARVs and other medicines were low. The 
participants attitudes towards reporting ADRs due to DDIs was poor, as not many participants reported 
experiences of ADRs regarding ARVs and other medicines. The poor awareness and reporting of ADRs 
may be due to low spontaneous reporting of ADRs by participants. Participants responses were low 
regarding awareness of ADRs reporting and how they can actively participate in reporting ADRs. It 
seems as though they rely on healthcare professionals to complete the ADR forms and hand them in. 
Furthermore, side effects and ADRs were used interchangeably, which could have caused confusion 
thereby acting as barriers to ADR reporting. Creating awareness about ADRs and what causes them 
through educating and counselling patients could be achieved by creating and placing educational 
posters around healthcare facilities. Patients can read the posters while waiting to collect their medicines 
which could then create awareness for them .Reporting of ADRs by patients to health care professionals 
and spontaneous reporting should be taught and encouraged. This will help to reduce the increasing 
yearly rates of morbidity and mortality due to ADRs in patients taking ARVs and other medicines. This 
study has revealed the need of ADRs reporting especially by patients, which will increase 
pharmacovigilance database that will further assist in monitoring the ADRs and side effects of 
medicines that were previously not reported during clinical trials. An in-depth investigation of ADRs 
of ARVs among patients is recommended to get a better understanding of how patients can handle 
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Appendix A: Questionnaire  
           
Questionnaire 
Awareness, attitudes, and experiences of patients taking antiretroviral towards adverse drug 
reactions at public health facility in KwaZulu-Natal 
This study is aimed to create awareness about adverse drug reactions and drug interactions amongst 
patients taking antiretroviral therapy and other medication. 
 
Researchers name: Malebogo Tlaila Code: ____________ 
 
 
1. Age (in years) 
1. > 20 ☐  2. 21-30 ☐  3. 31-40☐ 4. 41-50☐ 5. Above 51 ☐ 
2. Gender 
1. Male ☐    2. Female ☐  
3.Race 
1. Black  ☐ 
2. White  ☐ 
3. Coloured  ☐ 
4. Indian  ☐ 
5. Other (Please specify) 








3. Weight (kg) 
1. 40-60 ☐  2. 61-80☐  3. 81-99 ☐ 4.Above 100 ☐   
5. Level of education achieved 
1. Primary School ☐ 
2. Matric  ☐ 
3. Diploma  ☐ 
4. Bachelor  ☐ 
5. Certificate  ☐ 
6. No education ☐ 
7. Other (Please specify) 
________________________________ 
6. Employment status 
1. Unemployed   ☐ 
2. Self-employed ☐  
3. Fully employed ☐ 
 
7. If answered employed to question 6 above, Please indicate occupation  
1. Street vendor   ☐   
2. Domestic worker  ☐ 
3. Gardner   ☐ 
4. Teacher   ☐ 
5. Nurse   ☐ 






8. If unemployed, please indicate other sources of income 
1. No skill  ☐ 
2. Semi-skilled  ☐ 
3. Skilled  ☐ 
4. Other (Please specify) 
__________________________ 
9. Disease- conditions you are being treated  
9.1 HIV/AIDS  ☐  
9.2 Diabetes  ☐ 
9.3 Hypertension ☐ 
9.4 Tuberculosis ☐ 
9.5 Cholesterol ☐ 
9.6 Other (Please Specify) 
_______________________ 
10. Can you identify the medication you are on? 
1. Yes  ☐  
2. No  ☐ 
11. If yes to question 10 above, please indicate the type of medication you are taking  
 
11.a) Antiretroviral Medication Please Tick 
1 FDC/Atroiza/®Odiomune® 




Abacavir 300 mg + Lamivudine 150 mg 
 
3. Lamzid®/Duranavir® 
Lamivudine 150 mg + Zidovudine 300 mg 
 
4. Aluvia® 200/50mg  
5. Efavirenz 600 mg  





7. Tenofovir 300 mg  
8. Ritonavir 100mg  
9. Atazanavir 150 mg  
10. Zidovudine 300 mg  
 
11. b) Tuberculosis (TB) Medication 
1. Rifafour®  
2. Rifinah®  
3. Rifampicin  
4. Pyrazinamide  
5. Ethionamide  
6.Other (Please specify):  
 
11. c) Diabetic Medication 
1. Metformin  
2. Glimepiride  
3. Glibenclamide  
4. Other (Please specify):  
 
11. d) Hypertension Medication 
1.Hydrochlorothiazide  
2. Furosemide  
3. Enalapril  





5. Atenolol  








12. Has the antiretroviral medication you are taking been changed since you have been taking 
them? 
1. Yes  ☐ 
2. No  ☐ 
3. Not sure ☐ 
13. If yes to question 10 above, who changed the antiretroviral medication? 
1. Doctor ☐ 
2. Nurse ☐ 
3. Other (Please specify) 
______________________ 
14. Please reason indicate reason for changing the antiretroviral medication (You can tick more 
than one) 
14.1 Treatment failure  ☐ 
14.2 Side effects  ☐ 
14.3 Drug–drug interactions ☐ 
14.4 Drug-Food interactions ☐ 
11. d) Cholesterol Medication 
1. Simvastatin  
2. Atorvastatin  
3. Bezafibrate  





14.5 Drug-Herb interactions ☐ 
14.6 Adverse drug reaction ☐ 
14.7 Other (Please Specify) 
________________________ 
15. Has other medication, besides antiretroviral been changed? 
Yes  ☐ 
No ☐ 
16. If yes to question 15 above, please indicate reason for change (You can tick more than one) 
Treatment failure  ☐ 
Side Effects   ☐ 
Drug–drug interactions ☐ 
Drug-Food interactions ☐ 
Drug-Food interactions  ☐ 
Adverse Drug reaction ☐ 
Other (Please specify) 
________________________ 
 
B. i. Awareness of adverse drug reactions:  
 
17. Are you aware what ADR is? 
Yes  ☐ 
No ☐ 
18. If yes to question 17 above, indicate whether you agree, disagree or are not sure about this 
statement: 





An adverse drug reaction is an injury caused 
by taking a medication. It may occur 
following a single dose or prolonged 
administration of a drug or a combination of 
two or more drugs. 
   
 




20. If yes to question 19 above, please indicate who counselled you 
Doctor  ☐ 
Nurse  ☐ 
Pharmacist ☐ 
Other (Please specify) 
__________________________ 
21. Are you aware what causes ADR? 
Yes  ☐  
No ☐ 
22. If yes to the question 21 above, please indicate what causes ADR:  
Taking other medication with ARV 
Eating food that interacts with ARV 
Taking herbs that interact with ARV 
Medication overdose 
Other diseases 






23. Please indicate if the following signs are results of adverse drug reaction 
 
Vomiting  Peripheral neuropathy  
Diarrhoea  Uneven fat distribution  
Nausea  Hypertension  
Depression  Stroke  
Hallucinations  Renal failure  
Dizziness  Hepatitis  
Sleep disturbances  Anaemia  
Breaset development  Lactic Acidosis  
 
 
B. ii. Awareness of drug interactions leading to ADRs: 
 
24. Are you aware of drug interactions? 
Yes ☐ 
No ☐ 
25. If yes to question 24 above, please indicate if you agree, disagree or not sure about this 
statement: 
Statement Agree Disagree Not sure 
Drug interaction occurs in a situation 
in which a substance affects the 
activity of a drug when both are taken 
together. 
   
 
26. Which of the following types of drug interactions are you aware of? (You can choose more 
than one) 
Drug–drug interactions  ☐  





Drug-herb Interaction  ☐ 
Drug-disease interaction ☐ 
Other (Please specify) 
__________________________ 
 
27. Are you aware that the following drug combinations can cause drug interaction? (You can 






















































Atrozia®        
Dumiva®        
Lamzid®        
Aluvia®        
Efavirenz        
Nevirapine        
Tenovofir        
Ritonavir        
Atazanavir        
Zidovudine         
Rifafour®        
Rifinah®        
Rifampicin        
Pyrazinamide        
Ethionamide        
Metformin        
Glimepiride        
Hydrochlorothiazide        
Furosemide        
Enalapril        
Amlodipine        








28. Are you aware if the following food can interact with your antiretroviral medication? (Tick 
on the interaction you are aware of) 
 Grapefruit Alcohol Banana Caffeine Dairy Products 
Atrozia®      
Dumiva®      
Lamzid®      
Aluvia®      
Efavirenz      
Nevirapine      
Tenovofir      
Ritonavir      
Atazanavir      
Zidovudine       
Rifafour®      
Rifinah®      
Rifampicin      
Pyrazinamide      
Ethionamide      
Metformin      
Glimepiride      
Hydrochlorothiazide      
Furosemide      
Enalapril      
Amlodipine      
Atenolol      
Simvastatin      
Atorvastatin      
Bezafibrate      
Other (Please Specify): _____________________________________________ 
29. Are you aware if the following herbs can cause drug interactions? (Tick on the interaction you 
are aware of) 
Simvastatin        
Atorvastatin        












Atrozia®      
Dumiva®      
Lamzid®      
Aluvia®      
Efavirenz      
Nevirapine      
Tenovofir      
Ritonavir      
Atazanavir      
Zidovudine       
Rifafour®      
Rifinah®      
Rifampicin      
Pyrazinamide      
Ethionamide      
Metformin      
Glimepiride      
Hydrochlorothiazide      
Furosemide      
Enalapril      
Amlodipine      
Atenolol      
Simvastatin      
Atorvastatin      






Other (Please Specify): ______________________________________________ 
30. How often have you experienced adverse drug reactions?  
a. Weekly   ☐ 
b. Monthly  ☐ 
c. A few times a year☐  





 31. Have you experienced ADR? 
Yes  ☐  
No  ☐ 
 
32. If yes to question above 31, indicate which of the following you have experienced? 
Kidney failure   ☐ 
Inadequate blood supply ☐ 
Rash   ☐ 
Unexplained weight gain ☐ 
Diarrhoea   ☐ 
Vomiting   ☐ 
Other (Please Specify) 
_________________________ 





33. Have you ever been hospitalized due to ADR? 
Yes ☐ 
No ☐ 
34. Has your antiretroviral medicine been changed due to ADR? 
Yes ☐ 
No ☐ 





Other (Please specify): _______________________________ 
 
D. Attitudes towards adverse drug reactions regarding ARVs and other medicines 
 
36. Have you reported adverse drug reactions? 
Yes ☐ 
No ☐ 
37. If yes to question 35 above, how often have you reported adverse drug reactions?  
Weekly   ☐ 
Monthly  ☐ 
A few times a year ☐ 
Never   ☐ 
38. How did you report it? 
Told the Nurse  ☐ 
Doctor   ☐ 
 Pharmacist  ☐ 
Family    ☐ 





Ignored the reaction ☐ 
Other (Please specify) 
________________________ 
39. What was done after reporting it? 
Completed an adverse drug reaction form ☐ 
Received counselling    ☐ 
Medicines changed    ☐ 
Nothing was done    ☐ 
Other (Please specify) 
______________________________ 
 
40. I feel that the completed adverse drug reaction form can be submitted to:  
(You can choose more than one)  
Pharmacy Department  ☐ 
Medicines Control Council ☐ 
Drug Company   ☐ 
National Department of Health ☐ 






Appendix B: Participant Information Leaflet and Consent Form 
Participant Information Letter 
Awareness and attitudes of patients towards possible drug–drug interactions and adverse drug 
reactions at a selected public health facility in KwaZulu-Natal 
Hello! I would like to ask some of your time to read through this consent form requesting you to 
participate in our study. 
My name is Malebogo Tlaila. I am postgraduate student at the University of KwaZulu-Natal; 
Department of Pharmacy situated in Varsity drive Durban, 4091. You can freely contact me on 
tlailamalebogo@yahoo.com or my supervisor Dr E. Ojewole on Ojewolee@ukzn.ac.za in relation to 
this research study.  
You are invited to consider participating in a study that involves research about awareness, experiences 
and attitudes towards adverse drug reactions (ADRSs) 
The aim of the study is to evaluate the participants’ awareness and attitudes towards possible drug–drug 
interactions and adverse drug reactions.. The study is expected to enrol more than one hundred and 
eighty (180) participants from health care facilities in the eThekwini district, Clairwood Hospital, 
KwaZulu-Natal. It will involve questionnaires that you will be requested to answer honestly . The time 
requested to complete the questionnaire is 10 minutes. The study is not funded and is pursued for study 
purposes. 
The study will involve questions that may make you feel uncomfortable to answer; however, your 
honest response will help benefit the output of the study to give suitable recommendations.  
This study has been ethically reviewed and approved by the UKZN Humanities and Social Sciences 
Ethics Committee (awaiting approval number). 
In the event of any problems, questions or concerns you may contact the researcher at 
tlailamalebogo@yahoo.com or the UKZN Humanities and Social Research Ethics Committee 






HUMANITIES & SOCIAL SCIENCES RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604557- Fax: 27 31 2604609 
Email: HSSREC@ukzn.ac.za   
Consent form 
Date: 
Hello! I hope that you are feeling well today. I would like to ask some of your time to read through this 
consent form requesting you to participate in our study. 
My name is Malebogo Tlaila. I am postgraduate student at the University of KwaZulu-Natal; 
Department of Pharmacy situated in Varsity drive Durban, 4091. You can freely contact me on 
tlailamalebogo@yahoo.com in relation to this research project.  
You are invited to consider participating in a study that involves research about awareness and attitudes 
towards side effects and how people manage them.  
The aim of the study is to evaluate the participants’ awareness and attitudes towards possible drug–drug 
interactions and adverse drug reactions. Here onwards the term drug–drug interactions was 
interchangeably used with the term side effects. The study is expected to enrol more than three hundred 
participants from health care facilities in the eThekwini district. It will involve self-administered 
questionnaires that you will be requested to honestly answer. The time requested to complete the 
questionnaire is 10 minutes. The study is not funded and is pursued for study purposes. 
The study will involve questions that may make you feel uncomfortable to answer; however, your 
honest response will help benefit the output of the study to give suitable recommendations.  
This study has been ethically reviewed and approved by the UKZN Humanities and Social Sciences 
Research Ethics Committee (awaiting approval number). 
In the event of any problems, questions or concerns you may contact the researcher on 
tlailamalebogo@yahoo.com or the UKZN Humanities and Social Sciences Research Ethics Committee 





HUMANITIES & SOCIAL SCIENCES RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604557- Fax: 27 31 2604609 
Email: HSSREC@ukzn.ac.za   
Your participation is completely voluntary and you have the write to withdraw from the study at any 
point. There will be no penalty for sudden withdrawal from the study. Questionnaires that have been 
withdrawn from shall be considered incomplete and voided out from the study. 
The information given will be highly confidential and at no time will you be requested to identify 
yourself. Data collected will be safely stored at the School of Pharmacy. Electronic data will safely be 
stored in a secure database that will only be accessed by the researcher. The data will be discarded after 
5 years. 
 Please tick box 
I confirm that I understand the information sheet for the study above  
I understand that my participation is voluntary and that I can withdraw at 
any time without giving reason 
 
I agree that my data gathered in this study can be stored and may be used 
for future research. 
 
 
__________________________       ____________________ 
Signature of participant   Date 
__________________________       ____________________ 
Signature of Researcher    Date 
_________________________        ___________________ 













The National Institutes of Health (NIH) Office of Extramural Research
certifies that Malebogo Tlaila successfully completed the NIH Web-
based training course “Protecting Human Research Participants”.
Date of completion: 08/01/2015
Certification Number: 1807210





